4种呼吸道感染治疗方案的成本-效果分析

目的评价呼吸道感染的4种治疗方案的药物经济学效果。方法采用回顾性研究方法，选择114例呼吸道感染患者，按治疗方案分为4组（A，B，C，D组），分别观察其疗效并运用成本-效果分析法（CEA）进行分析。结果4组治疗方案成本分别为190．40，403．20，1380．96，174．72元，临床有效率分别为86．7％，86．7％，90．0％，62．5％，成本-效果比（C／E）分别为2．19，4．65，15．34，2．79，A，B，C组相对于D组的增量成本一效果比（△C／△E）分别为0．65，9．44，43．86。结论A组（头孢曲松组方案）为最佳的治疗方案。

Cost- effectiveness Analysis of Four Therapeutic Schemes for Respiratory Tract Infection

Objective To evaluate the pharmacoeconomic effectiveness of the four therapeutic schemes for respiratoy tract infections. Methods A retrospective study was conducted, in which a total of 114 cases with respiratory tract infection were enrolled and randomly assigned to receive each of the following 4 therapies （group A, B, C, D）. The therapeutic effects were monitored and the cost-effectiveness analysis was adopted on the four treatment schemes. Results The costs of the four regimens were 190. 40 yuan, 403.20 yuan, 1 380. 96 yuan and 174. 72 yuan. The clinical effective rates were 86. 7%, 86. 7%, 90. 0% and 62. 5% ,respectively. The cost - effectiveness rates （ C/ E） were 2. 19, 4. 65, 15.34 and 2. 79,respectively. And the incremental cost - effectiveness rates （/△ C/△ E） of group A, B and C were 0. 65, 9.44 and 43.86 respectively, as against group D. Conclusion Group A （ceftriaxone treatment group） is the best therapeutic scheme.